Micafungin therapy in a critically ill, morbidly obese patient

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2678-2680

  Zomp, Amanda ^a,e   Bookstaver, P Brandon ^b   Ahmed, Yasir ^c   Turner, J Elliot ^a,b   King, Christie ^d,f  

^a Palmetto Health Richland   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e TAMPA GENERAL HOSPITAL   (United States)

^f Walmart Corporation   (United States)

Author keywords

Candidiasis; Echinocandins; Obesity; Pharmacokinetics

Indexed keywords

MICAFUNGIN;

ADULT; ARTIFICIAL VENTILATION; BLOOD CELL COUNT; BLOOD CULTURE; CANDIDA GLABRATA; CASE REPORT; CELLULITIS; FEMALE; FLUID RESUSCITATION; HUMAN; LETTER; LEUKOCYTOSIS; MORBID OBESITY; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SEPTIC SHOCK; URINALYSIS; URINE CULTURE;

ADULT; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; CRITICAL ILLNESS; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; OBESITY, MORBID;

EID: 80054709767     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr323     Document Type: Letter

References (10)

1. CDC. Overweight and Obesity: Data and Statistics. http://www.cdc.gov/obesity/data/index.html (1 March 2011, date last accessed).
2. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
3. Pappas PG, Kauffman CA, Andes D et al Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
4. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25: 112-8.
5. Micafungin (Package Insert). Deerfield, IL, USA: Astellas Pharma US, Inc., 2008.
6. Hiemenz J, Cagnoni P, Simpson D et al Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331-6.
7. Gumbo T, Hiemenz J, Ma L et al Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 2008; 60: 329-31.
8. Sirohi B, Powles RL, Chopra R et al A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 47-51.
9. Oliveira ER, Fothergill A, Kirkpatrick WR et al Antifungal susceptibility testing of micafungin against Candida glabrata isolates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 457-9.
10. Ishikawa J, Maeda T, Matsumura I et al Antifungal activity of micafungin in serum. Antimicrob Agents Chemother 2009; 53: 4559-62.